Navigation Links
'1 pill can kill': Effects of unintentional opioid exposure in young children
Date:8/28/2013

Cincinnati, OH, August 29, 2013 -- Medication poisonings among children are an important public health problem. During 2010-2011, an average of 1500 children under 6 years of age was evaluated in emergency departments each year due to unintentional exposure to buprenorphine. Ingestion of strong opioids, such as buprenorphine, can cause central nervous system depression, respiratory depression, and death in young children. In a new study scheduled for publication in The Journal of Pediatrics, researchers study how young children are gaining access to buprenorphine, as well as the effects of unintentional exposure to its different formulations.

Buprenorphine (or the buprenorphine-naloxone combination form), usually sold as a tablet or film strip, is used to treat adults who are addicted to opioids, such as prescription pain medication and heroin. Tablets typically are dispensed in 30-day supply bottles with child-resistant caps, and film strips are dispensed in single-dose, child-resistant foil packs. Dr. Eric Lavonas and colleagues from the Rocky Mountain Poison and Drug Center, the University of Colorado School of Medicine, the University of Oklahoma, Integris Baptist Medical Center, Degge Group, and Venebio Group studied 2380 cases of unintentional exposure to buprenorphine in any form involving children under 6 years of age. The average age of the children was 2 years. Common effects of buprenorphine exposure were lethargy, respiratory depression, miosis (small pupils), and vomiting. Although most children had good outcomes, 587 children were admitted to the intensive care unit and 4 children died.

The researchers found that children were 3.5 to 8.8 times more likely to accidentally ingest the tablets as have unintentional exposure to film strips; 95% of cases involved tablets. In 57% of the cases, at least one root cause for the exposure was identified: 415 cases involved medication stored in sight, in 110 cases the child accessed the medication from a bag or purse, and in 75 cases the medication was not stored in the original packaging. Although most exposures were in the child's own home, 5% of exposures occurred while the child was being watched by another caregiver.

Buprenorphine can be helpful in adult patients who are struggling with addiction issues, but it should not be accessible by children because even a single dose can be life-threatening. Therefore, it is important for all caregivers to be especially vigilant in keeping medications in their original packaging and up, away, and out of sight of children. Although this study focused on just one medication used in a specific population, other more widely used medications, such as those used to treat high blood pressure or diabetes, can be as harmful in young children. According to Dr. Lavonas, "This study underscores the value of providing medications that are particularly dangerous when taken by children, in single dose, child resistant packaging." This approach is likely to be more effective at reducing unintentional exposure than additional efforts at education.


'/>"/>

Contact: Becky Lindeman
journal.pediatrics@cchmc.org
513-636-7140
Elsevier Health Sciences
Source:Eurekalert

Related biology news :

1. Study adds lung damage to harmful effects of arsenic
2. New tests for determining health and environmental effects of nanomaterials
3. Chemotherapy before radiotherapy for testicular cancer could reduce long-term side-effects
4. Researchers study seleniums effects on horses
5. Study explores effects of review setting on scientific peer review
6. Rapamycin: Limited anti-aging effects
7. Key target responsible for triggering detrimental effects in brain trauma identified
8. Adverse effects of phthalates on ovarian response to IVF
9. Time is of the essence for reducing the long-term effects of iron deficiency
10. Patients use OTC NSAIDs even when they have a high risk of serious side effects
11. Hidden effects of climate change may threaten eelgrass meadows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2019)... ... 16, 2019 , ... LeadingBiotech , an exclusive event ... its NY/NJ CEO conference to be held on November 5, 2019 ... The event offers senior-level industry leaders a unique opportunity to collaborate, build partnerships ...
(Date:10/11/2019)... ... , ... Advanced Clinical, a clinical research services organization, is ... appointed Therapeutic Lead for Oncology. Dr. Tyan brings a wealth of practical, therapeutic, ... delivery credentials previously offered at Advanced Clinical. , Dr. Tyan has worked extensively ...
(Date:10/10/2019)... ... October 10, 2019 , ... Mindray, a ... attendees of the American Society of Anesthesiologists 2019 Annual Meeting to visit exhibit ... 19-21 in Orlando, Florida, and will provide more than 14,000 healthcare professionals from ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... ... October 02, 2019 , ... Today marked the ... is enabling clinical program outsourcing success by cultivating radical improvements in leadership, staff, ... veteran executive Brenda Reese, phaseUP™ brings clients deep, broad and unique expertise in ...
(Date:10/3/2019)... (PRWEB) , ... October 02, 2019 , ... eKare’s inSight® ... NHS Digital Health Accelerator run by the East Midlands Academic Health Science Network (EMAHSN), ... adoption of technology in NHS by providing support to develop and deploy solutions to ...
(Date:10/3/2019)... ... 2019 , ... Yesterday, at the 2019 meeting of Outsourcing in Clinical Trials ... Sherley, M.D., Ph.D., discussed important design factors that currently limit the success of early ... suppliers of clinical trials, in his talk Dr. Sherley focused on the ...
(Date:9/24/2019)... WEST LAFAYETTE, Ind. (PRWEB) , ... ... ... Pharma LLC will be presenting their latest research in the area of ... Monday, November 4th, Dr. Pamela Smith, COO of Improved Pharma, will present ...
Breaking Biology Technology: